3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
117
Colonic Neoplasms
30
Rectal Neoplasms
27
Neoplasms
20
Neoplasm Metastasis
19
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Cholangiocarcinoma
7
Colorectal Cancer Metastatic
6
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Biliary Tract Neoplasms
2
Thyroid Neoplasms
1
Recurrence
1
Pancreatic Adenocarcinoma
1
Oesophago-gastric Cancer
1
Neoplasms, Second Primary
1
Kidney Neoplasms
1
KRAS and NRAS Wild-type Colorectal Cancer
1
Histiocytosis
1
Gallbladder Neoplasms
1
Exanthema
1
Esophageal Squamous Cell Carcinoma
1
Elderly Metastatic Colorectal Cancer Patients
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Interventions
Cisplatin
116
Radiotherapy
84
Paclitaxel
77
Fluorouracil
62
Carboplatin
41
Drug Therapy
38
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Neoadjuvant Therapy
24
Oxaliplatin
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
18
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
16
Nivolumab
16
Leucovorin
15
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
Immune Checkpoint Inhibitors
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Panitumumab
×
Gastrointestinal
×
Clear all
NCT01627379
2018-03-02
POWER
AIO-Studien-gGmbH
Phase 3
Terminated
300 enrolled